Related Experiment Video
Updated: Apr 18, 2026
13:05
Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids
Published on: June 28, 2019
8.9K
Omega-3-carboxylic acid (Epanova) for hypertriglyceridemia
1From the *Department of Pharmacy, Winthrop University Hospital, Mineola, NY; and †Department of Clinical Pharmacy Practice, College of Pharmacy & Health Sciences, St. John's University, Queens, NY.
Cardiology in Review
|January 13, 2015
Summary
Omega-3-carboxylic acid (Epanova) effectively lowers triglyceride levels in patients with severe hypertriglyceridemia. While generally well-tolerated, its long-term cardiovascular and pancreatitis benefits require further investigation.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Hypertriglyceridemia is a common condition linked to diabetes, obesity, and inactivity.
- Elevated triglycerides increase the risk of coronary artery disease and pancreatitis.
Purpose of the Study:
- To evaluate omega-3-carboxylic acid (Epanova) as a treatment for severe hypertriglyceridemia.
- To assess its efficacy, bioavailability, and safety compared to other formulations.
Main Methods:
- A placebo-controlled study assessed TG reduction at approved dosages.
- Bioavailability was compared with omega-3-acid ethyl ester (Lovaza).
- Statin co-therapy effects were also evaluated.
Main Results:
- Omega-3-carboxylic acid reduced baseline TG by 25-30% and an additional 8-15% with statins.
- It demonstrated a potentially better bioavailability profile than Lovaza.
- Gastrointestinal side effects were the most common adverse events.
Conclusions:
- Omega-3-carboxylic acid is an alternative adjunct therapy for severe hypertriglyceridemia.
- Evidence regarding its impact on cardiovascular events and pancreatitis risk is currently limited.
- Further research is needed to compare its clinical benefits against other omega-3s.
Related Concept Videos
01:06Lipid Digestion
108.4K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
108.4K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
01:31Lipid-derived Compounds in the Human Body
7.5K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
7.5K
01:26Atherosclerosis III: Management
642
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
642
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
01:24Lipid Absorption
3.8K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.8K